Day: May 6, 2024

OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions received in the U.S. BRISBANE, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2024 financial results and highlighted recent corporate achievements. “We are excited that OJEMDA is now approved and available here in the U.S., and we are grateful to the members of the pediatric brain tumor community whose support of the program has been invaluable,” said Jeremy Bender, Ph.D., chief executive officer...

ST. LOUIS, May 06, 2024 (GLOBE NEWSWIRE) —  BellRing Brands, Inc. (NYSE:BRBR) (“BellRing”), a holding company operating in the global convenient nutrition category, today reported results for the second fiscal quarter ended March 31, 2024. Highlights: Second quarter net sales of $494.6 million Operating profit of $91.0 million, net earnings of $57.2 million and Adjusted EBITDA* of $103.7 million Raised fiscal year 2024 net sales outlook to $1.93-$1.99 billion and Adjusted EBITDA* outlook to $400-$420 million *Adjusted EBITDA is a non-GAAP measure. For additional information regarding non-GAAP measures, see the related explanations presented under “Use of Non-GAAP Measures” later in this release. BellRing provides Adjusted EBITDA guidance only on a non-GAAP basis and does not provide a reconciliation of its forward-looking Adjusted...

LAFAYETTE, La., May 06, 2024 (GLOBE NEWSWIRE) — Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2024. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2024 were $50.6 million, representing an increase of $11.0 million, or 28%, over net revenues reported for the comparable quarter ended March 31, 2023. Net income for the quarter ended March 31, 2024 totaled $1.6 million. Adjusted EBITDA for the quarter ended March 31, 2024 totaled $10.1 million, a 21% increase as compared to the quarter ended March 31, 2023. A reconciliation of reported non-GAAP financial measures to their...

FORT MYERS, Fla., May 06, 2024 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico”, the “Company”, “we”, or “our”) (Nasdaq: ALCO) today announces financial results for the second quarter of fiscal year 2024 and the six months ended March 31, 2024, the highlights of which are as follows: Revenues of $32.1 million for the six months ended March 31, 2024 were relatively flat as compared to $31.9 million in the six months ended March 31, 2023. Net income attributable to Alico, Inc. common stockholders of $27.1 million and EBITDA of $47.3 million for the six months ended March 31, 2024. After adjusting for certain items, the Company reports Adjusted EBITDA of $(1.0) million for the six months ended March 31, 2024. Lower than anticipated box production for the Valencia Harvest, as the Company continues to recover from the effects of Hurricane Ian,...

Business transformation continues to drive improved profitability and new business wins CHARLOTTE, N.C., May 06, 2024 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, today reported its financial results for the first quarter ended March 31, 2024. Highlights Strategic transformation program drove another quarter of improved results, 3rd quarter in a row; First quarter net sales of $121.2 million, down 4.6% versus prior year, driven largely by rationalized volume; First quarter operating loss of $4.8 million, an improvement of $2.3 million versus prior year; First quarter adjusted EBITDA of $11.3 million, an improvement of 38.9% versus prior year; First quarter free cash flow of $0.3 million, an improvement of $4.0 million...

~ Crude Oil and Boe Sales Volumes Exceed High End of Q1 Guidance ~~ LOE per Boe and Capital Spending Below Low End of Q1 Guidance ~ THE WOODLANDS, Texas, May 06, 2024 (GLOBE NEWSWIRE) — Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today reported operational and financial results for the first quarter of 2024. Also, the Company provided an outlook for the second quarter of 2024 and reiterated its operational and financial guidance for the full year of 2024. First Quarter 2024 Highlights Sales of 13,394 barrels of oil per day (“Bo/d”), exceeding high end of the Company’s guidance by 5%; Total sales volumes of 19,034 barrels of oil equivalent per day (“Boe/d”) (70% oil), exceeding high end of guidance by 3%; Reported net income of $5.5 million, or $0.03 per diluted share, which included a before-tax loss on...

CALGARY, Alberta, May 06, 2024 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) announces first quarter results for the period ended March 31, 2024. President’s Message $74 million in revenue; $54 million in funds from operations ($0.36/share) (1); $41 million in dividends paid ($0.27/share); 14,714 boe/d total production (63% oil and NGL and 37% natural gas); 9,593 boe/d in Canada (56% oil and NGL and 44% natural gas); 5,121 boe/d in the U.S. (78% oil and NGL and 22% natural gas); and $54.81/boe average realized price ($69.19/boe in the U.S. and $47.13/boe in Canada). Our North American portfolio continues to attract drilling activity with 300 gross (6.4 net) wells drilled on our royalty lands in Q1-2024, a 15% increase over the previous quarter. Leasing of our mineral title lands continues to...

Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced unaudited financial and operational results for the first quarter ended March 31, 2024. Recent Financial and Operational Highlights Achieved first quarter 2024 sepsis product revenue of $2.1 million, representing growth of 25% compared to the prior year period and sequential growth of 23% compared to the fourth quarter of 2023, led by T2Candida Panel sales and strong T2Resistance Panel sales internationally. Executed contracts for 8 T2Dx® Instruments during the first quarter, including 5 T2Dx Instruments...